GYNE-LOTRIMIN 3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 (GYNE-LOTRIMIN 3).
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
| Metabolism | Minimal systemic absorption after intravaginal administration; primarily metabolized in the liver via hepatic microsomal enzymes. |
| Excretion | Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug. |
| Half-life | Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance. |
| Protein binding | Clotrimazole is 90–95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.1–0.2 L/kg after systemic absorption; however, for vaginal administration, systemic absorption is negligible, so Vd is not clinically meaningful. |
| Bioavailability | Systemic bioavailability after intravaginal administration is <0.5% due to poor absorption through vaginal mucosa and extensive first-pass metabolism. |
| Onset of Action | Onset of symptomatic relief (itching, discharge) occurs within 24–72 hours after intravaginal insertion; significant clinical improvement typically seen within 3 days. |
| Duration of Action | Therapeutic effect persists for 7–14 days after a single 3-day course, based on continued antifungal activity and resolution of infection; recurrence possible if reinfection occurs. |
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment (Child-Pugh A, B, or C). |
| Pediatric use | Intravaginal: children ≥12 years: same as adult dosing (3-day regimen). Children <12 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use same regimen as younger adults. Consider renal and hepatic function, though no adjustment needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 (GYNE-LOTRIMIN 3).
| Breastfeeding | Clotrimazole is minimally absorbed systemically after vaginal administration; M/P ratio is not established. It is not excreted into breast milk in significant amounts. Considered compatible with breastfeeding; apply after nursing to minimize infant exposure. |
| Teratogenic Risk | Clotrimazole (active ingredient) is classified as Pregnancy Category B. There is no evidence of teratogenicity in animal studies; limited human data show no increased risk of major birth defects. Avoid intravaginal use during first trimester unless clearly needed; use during second and third trimesters is generally considered safe. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to clotrimazole or any component.","Pregnancy (first trimester only if essential; second and third trimesters with caution).","Do not use in prepubertal girls without medical advice."]
| Precautions | ["Do not use if abdominal pain, fever, or foul-smelling discharge is present.","Discontinue if sensitivity or irritation occurs.","Not for prevention of sexually transmitted diseases."] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring required for standard use. In cases of prolonged use or high-dose regimens, monitor for local irritation or hypersensitivity reactions. |
| Fertility Effects | No known adverse effects on fertility. Clotrimazole does not affect ovulation, implantation, or spermatogenesis when used vaginally. |